OIP-193: 2026 Funding Proposal

Summary:

Approve funding for FY26 and renew the Association's credit line approved in 2025.

Background:

Following the successful completion of OIP-179: Funding Proposal (2025), the Association seeks funding approval for the 2026 Fiscal year. Budgeted spend is expected to be similar to the table below, with the possibility to flex as needed for additional dev and association resource needs, within reason.

As with the 2025 proposal, variable expenses that are not included in the these projections, but are within the purview of the association are:

1. Immunefi Bug Bounty Payouts + fees (fees are dependent on payouts)
2. Unforeseen Legal Expenses
3. Audits, given scope and development (OIP-98 establishes a $500k yearly budget for audits, a more realistic budgeted spend is displayed in the table)
   For context, you can review the 2025 spend here
   Original 2025 Budget Proposal can be found here

Proposal:

1. Fund the association incrementally to cover the budgeted spend, and
2. Renew the Association's credit line that was approved in 2025
   (Revolving line of credit of up to 500,000 OHM during Fiscal Year 2026, with the option to purchase borrowed OHM at the greater of 12 USDS or liquid backing). Same terms as 2025.
   Note: This funding does not include funding for Callisto, a separate proposal will follow.

On Use of Loan Proceeds:

Tokens borrowed by the Association will be used for strategic over-the-counter (OTC) deals with funds, market makers, or exchanges, at the Associations discretion. Tokens may also be utilized to a lesser degree in employee option compensation packages.
The Association will only utilize tokens when strictly necessary from a funding perspective, or exceptionally advantageous from an alignment perspective. The Association has a long history of responsible spending. In the case of leftover funds at year end FY26, they are to be returned to the treasury or rolled over into FY27, at governance instruction.

Motivation:

Provide the Olympus Association with backing-neutral funding for FY26 to allow it to continue development of the Olympus protocol.